2 Reasons to Buy Exact Sciences Stock, and 1 Reason to Sell

Thanks to its highly sensitive tests that can detect cancer earlier, less invasively, and with more confidence than the alternatives, Exact Sciences (NASDAQ: EXAS) has already made a home for itself in the oncology screening market. Its operations are perennially unprofitable, not to mention that its pace of revenue growth is often meandering. Are these blemishes dealbreakers, or are they bumps in the road along the trajectory of a growth stock?